Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042).

Weber, Damien Charles; Ares, Carmen; Villa, Salvador; Peerdeman, Saskia M; Renard, Laurette; Baumert, Brigitta G; Lucas, Anna; Veninga, Theo; Pica, Alessia; Jefferies, Sarah; Ricardi, Umberto; Miralbell, Raymond; Stelmes, Jean-Jacques; Liu, Yan; Collette, Laurence; Collette, Sandra (2018). Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiotherapy and oncology, 128(2), pp. 260-265. Elsevier 10.1016/j.radonc.2018.06.018

[img] Text
1-s2.0-S0167814018333334-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (643kB) | Request a copy

PURPOSE The therapeutic strategy for non-benign meningiomas is controversial. The objective of this study was to prospectively investigate the impact of high dose radiation therapy (RT) on the progression-free survival (PFS) rate at 3 years in WHO grade II and III meningioma patients. MATERIALS AND METHODS In this multi-cohorts non-randomized phase II and observational study, non-benign meningioma patients were treated according to their WHO grade and Simpson's grade. Patients with atypical meningioma (WHO grade II) and Simpson's grade 1-3 [Arm 1] entered the non-randomized phase II study designed to show a 3-year PFS > 70% (primary endpoint). All other patients entered the 3 observational cohorts: WHO grade II Simpson grade 4-5 [Arm 2] and Grade III Simpson grade 1-3 or 4-5 [Arm 3&4] in which few patients were expected. RESULTS Between 02/2008 and 06/2013, 78 patients were enrolled into the study. This report focuses on the 56 (median age, 54 years) eligible patients with WHO grade II Simpson's grade 1-3 meningioma who received RT (60 Gy). At a median follow up of 5.1 years, the estimated 3-year PFS is 88.7%, hence significantly greater than 70%. Eight (14.3%) treatment failures were observed. The 3-year overall survival was 98.2%. The rate of late signs and symptoms grade 3 or more was 14.3%. CONCLUSIONS These data show that 3-year PFS for WHO grade II meningioma patients undergoing a complete resection (Simpson I-III) is superior to 70% when treated with high-dose (60 Gy) RT.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Weber, Damien Charles and Pica, Alessia

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0167-8140

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

11 Jul 2018 11:22

Last Modified:

10 Aug 2018 01:32

Publisher DOI:

10.1016/j.radonc.2018.06.018

PubMed ID:

29960684

Uncontrolled Keywords:

Atypical meningioma Dose escalation Malignant meningioma Observational study Phase II trial Radiotherapy

BORIS DOI:

10.7892/boris.118493

URI:

https://boris.unibe.ch/id/eprint/118493

Actions (login required)

Edit item Edit item
Provide Feedback